Absence of nuclear p16 is a diagnostic and independent prognostic biomarker in squamous cell carcinoma of the cervix

dc.contributor.authorMendaza, Saioa
dc.contributor.authorFernández Irigoyen, Joaquín
dc.contributor.authorSantamaría, Enrique
dc.contributor.authorZudaire, Tamara
dc.contributor.authorGuarch Troyas, Rosa María
dc.contributor.authorGuerrero-Setas, David
dc.contributor.authorVidal-Bel, August
dc.contributor.authorSantos-Salas, José
dc.contributor.authorMatias-Guiu, Xavier, 1958-
dc.contributor.authorAusin, Karina
dc.contributor.authorDíaz de Cerio, María José
dc.contributor.authorMartín-Sánchez, Esperanza
dc.date.accessioned2020-12-11T15:08:44Z
dc.date.available2020-12-11T15:08:44Z
dc.date.issued2020-03-19
dc.date.updated2020-12-11T15:08:44Z
dc.description.abstractThe tumor-suppressor protein p16 is paradoxically overexpressed in cervical cancer (CC). Despite its potential as a biomarker, its clinical value and the reasons for its failure in tumor suppression remain unclear. Our purpose was to determine p16 clinical and biological significance in CC. p16 expression pattern was examined by immunohistochemistry in 78 CC cases (high-grade squamous intraepithelial lesions (HSILs) and squamous cell carcinomas of the cervix -SCCCs). CC cell proliferation and invasion were monitored by real-time cell analysis and Transwell® invasion assay, respectively. Cytoplasmic p16 interactors were identified from immunoprecipitated extracts by liquid chromatography-tandem mass spectrometry, and colocalization was confirmed by double-immunofluorescence. We observed that SCCCs showed significantly more cytoplasmic than nuclear p16 expression than HSILs. Importantly, nuclear p16 absence significantly predicted poor outcome in SCCC patients irrespective of other clinical parameters. Moreover, we demonstrated that cytoplasmic p16 interacted with CDK4 and other unreported proteins, such as BANF1, AKAP8 and AGTRAP, which could sequester p16 to avoid nuclear translocation, and then, impair its anti-tumor function. Our results suggest that the absence of nuclear p16 could be a diagnostic biomarker between HSIL and SCCC, and an independent prognostic biomarker in SCCC; and explain why p16 overexpression fails to stop CC growth.
dc.format.extent17 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec701336
dc.identifier.issn1661-6596
dc.identifier.pmid32204550
dc.identifier.urihttps://hdl.handle.net/2445/172684
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms21062125
dc.relation.ispartofInternational Journal of Molecular Sciences, 2020, vol. 21, num. 6, p. 2125
dc.relation.urihttps://doi.org/10.3390/ijms21062125
dc.rightscc-by (c) Mendaza, Saioa et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationCèl·lules canceroses
dc.subject.classificationCàncer de coll uterí
dc.subject.classificationDiagnòstic
dc.subject.otherCancer cells
dc.subject.otherCervix cancer
dc.subject.otherDiagnosis
dc.titleAbsence of nuclear p16 is a diagnostic and independent prognostic biomarker in squamous cell carcinoma of the cervix
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
701336.pdf
Mida:
1.77 MB
Format:
Adobe Portable Document Format